Lu Shen
Impact in
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
- Pharmacology 12
- Pharmacogenetics and Drug Metabolism 11
- Oncology 27
- Drug Transport and Resistance Mechanisms 8
- Journals
- PLoS ONE (8 papers)Translational Psychiatry (3 papers)Toxicology Letters (3 papers)Frontiers in Pharmacology (3 papers)Genomics (3 papers)
- Partner nations
- ChinaUnited StatesThailand
In The Last Decade
Lu Shen
101 papers receiving 2.2k citations
Hit Papers
Peers
Comparison fields: 5 of 143
- Pharmacology 386
- Cancer Research 343
- Molecular Biology 976
- Oncology 355
- Endocrinology, Diabetes and Metabolism 185
Countries citing papers authored by Lu Shen
This map shows the geographic impact of Lu Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Shen more than expected).
Fields of papers citing papers by Lu Shen
This network shows the impact of papers produced by Lu Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Shen. The network helps show where Lu Shen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lu Shen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 6 | |
| 4 | 2021 | 1 | |
| 5 | 2021 | 3 | |
| 6 | Anti-Breast Cancer Effect of 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione in vivo and in vitro Through MAPK Signaling Pathway | 2020 | 2 |
| 7 | 2020 | 84 | |
| 8 | MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma | 2020 | 1 |
| 9 | 2019 | 20 | |
| 10 | 2018 | 41 | |
| 11 | 2018 | 3 | |
| 12 | 2018 | 8 | |
| 13 | [Guideline for diagnosis and treatment of ALK positive non-small cell lung cancer in China]. | 2015 | 3 |
| 14 | Literature Analysis of Clinical Application and Adverse Drug Reaction/Event of Lianhua Qingwen Capsule | 2015 | 4 |
| 15 | 2015 | 13 | |
| 16 | 2015 | 31 | |
| 17 | 2014 | 16 | |
| 18 | 2014 | 4 | |
| 19 | 2012 | 45 | |
| 20 | 2012 | 26 |
About Lu Shen
Lu Shen is a scholar working on Pharmacology, Oncology, Cancer Research, Genetics and Molecular Biology, having authored 106 papers that have together received 2.3k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (11 papers), Drug Transport and Resistance Mechanisms (8 papers), Lung Cancer Treatments and Mutations (8 papers), Genetic factors in colorectal cancer (6 papers), RNA modifications and cancer (6 papers), MicroRNA in disease regulation (6 papers), Schizophrenia research and treatment (6 papers) and DNA Repair Mechanisms (5 papers). The work is most often cited by research in Pharmacology (386 citations), Cancer Research (343 citations), Molecular Biology (976 citations), Oncology (355 citations) and Endocrinology, Diabetes and Metabolism (185 citations). Lu Shen has collaborated with scholars based in China, United States and Thailand. Frequent co-authors include Shengying Qin, Lin He, Mo Li, Cong Huai, Na Zhang, Mingzhe Zhao, Yingtian Zhang, Xianglong Zhao, Jingsong Ma and Bixuan Jiang. Their work appears in journals such as PLoS ONE, Translational Psychiatry, Toxicology Letters, Frontiers in Pharmacology and Genomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.